MarketPulse
A

$AMRN

1 article found
0 positive
1 negative
0 neutral
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Amarin's Vascepa Faces Generic Onslaught: Single-Drug Dependency Poses Existential Risk

Amarin's sole drug Vascepa faces generic competition, causing revenue to plummet 36% to $183 million in 2025, raising serious concerns about the company's single-product vulnerability.
PFEAMRNrevenue declinerestructuring